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If scientists were given free rein in the biotech world
they would probably come up with companies like
ARIAD Pharmaceuticals, Inc. (Cambridge, MA, USA).
Smart ideas, original research, and rigorous papers in
high pro¢le journals have been the hallmarks of ARIAD’s
8 years of existence.
Clinical trials have, however, been less evident. ARIAD
has tackled two tough ¢elds ^ designing small molecules to
alter signal transduction, and creating a regulatory system
for gene therapy ^ and has just recently started its ¢rst
phase II trial.
If investors are getting anxious, they should probably
stay patient for just a little longer. ARIAD’s hard work is
suddenly paying o¡ in many areas at once. A promising
osteoporosis drug enters the clinic in 2001, as do planned
trials of the company’s most exciting work, which involves
small molecule regulation of gene therapy. ARIAD’s sys-
tem may not be needed unless, and until, garden-variety,
unregulated gene therapy proves that it can induce sus-
tained and useful expression levels in humans subjects.
ARIAD is ready to pounce with their regulation technol-
ogy as soon as that fateful day arrives. They are hoping
that it is soon.
The promise of proximity
ARIAD started out as a signal transduction company.
The Src kinase binding osteoporosis drug, and several
other drug candidates not discussed in this article, ¢t
this mold. But in November 1993, Stuart Schreiber2 (Har-
vard University, Cambridge, MA, USA) and Gerald Crab-
tree (Stanford University, Stanford, CA, USA) published
a paper in Science that got ARIAD involved in the ex-
panding ¢eld of gene therapy. Schreiber and Crabtree used
small molecule dimerizing ligands to bring together pro-
teins (such as growth factor receptors or transcription fac-
tors) that are activated by such proximity.
A generic dimerizing system requires that binding sites
for the dimerizers be added to the target proteins. To get
these modi¢ed proteins into the cells of patients requires
gene therapy. By 1994, ARIAD’s gene therapy program
had started.
The planned treatment regimen is an initial dose of gene
therapy followed by months or years of pills. If the deliv-
ered genes stick around for long enough, the pills will take
care of regulating how much protein is produced from
those genes.
ARIAD can control gene therapy, but gene therapy itself
needs to be proven in the clinic
The treatment is primarily a replacement for injected
proteins. In the 1990s, injected proteins were the success
story, and gene therapy the sob story. But ARIAD’s vice
president of gene therapy Tim Clackson says that there are
multiple reasons why regulated gene therapy will triumph.
Many proteins, he says, have such a narrow therapeutic
range that injecting a bolus of protein will lead to toxicity,
periods of insu⁄cient therapy, or both. For longer-term
treatments, patient compliance with daily injections be-
comes a problem. Gene therapy o¡ers a once-o¡ injection
1074-5521 / 01 / $ ^ see front matter ß 2001 Elsevier Science Ltd. All rights reserved.
PII: S 1 0 7 4 - 5 5 2 1 ( 0 0 ) 0 0 0 5 9 - 4
1 A to A of Biotech. Innovations started 4 years ago with a column on
A¡ymax, and now ¢nishes 48 companies later with a pro¢le of
ARIAD. I’ve had a great time writing these columns, and thank
you for your interest and feedback. Links to all articles in the series
can be found at http://www.biotext.com/list.html.
E-mail : wells@biotext.com
2 Stuart Schreiber is both the editor of this journal and the chairman of
ARIAD’s board of scienti¢c and medical advisers. This pro¢le was,
however, written by a freelance contributor, and neither the choice of
the company as a subject nor the content of the article were in£u-
enced by any of the editors of this journal.
CHBIOL 56 7-3-01
Chemistry & Biology 8 (2001) 117^119
www.elsevier.com/locate/chembiol
that can be localized, but it comes with the same bolus
problem, and a concern that there is no way of turning the
whole thing o¡. ‘‘With something (as potent as) Epo (er-
ythropoietin) you absolutely can’t have an unregulated
gene therapy,’’ says Clackson.
Coming ready or not
In November 1993 the logic of the ARIAD approach
was already substantially in place. The following 7 years
have seen a lot of tinkering, such as the addition of a
‘bump’ to the dimerizer and a ‘hole’ to the binding pro-
tein, so that the natural version of the protein is not af-
fected by the added drug. Progress, says CEO Harvey
Berger, ‘‘may have been a little slower than we would
have liked.’’ But ARIAD’s progress is comparable, he
says, to that of other companies tackling new areas,
such as Tularik, Inc. (South San Francisco, CA, USA).
‘‘If there is one very clear message, it’s that ARIAD
took on a very tough area of science. (ARIAD and Tular-
ik) both went down some paths that didn’t work out, and
ARIAD had the added complexity of gene therapy being
one of the areas we are pursuing.’’
ARIAD must perfect both gene product and small mol-
ecule activator, and prove that both are safe. But it is a
third component ^ the method for delivering the gene ^
that has been slowing things up. ARIAD has been waiting
for gene therapists to make a vector that produces protein
for long enough to warrant regulation.
‘‘Some people say we are running before we can walk,’’
says Clackson. ‘‘Our feeling is that gene therapy is now a
reality, and we want to be poised and ready when the call
comes for greater safety and control.’’
‘‘It was a fair criticism a couple of years ago,’’ continues
Clackson, ‘‘but now the future has arrived.’’ Berger agrees.
‘‘I think there are clearly gene delivery systems that
work,’’ he says. ‘‘AAV (adeno-associated virus), I think,
is ready for prime time, is already in prime time. The
challenge now is to charge forward with clinical trials.’’
Once ARIAD successfully regulates the transcription of
one gene, others should follow rapidly. But the ¢rst proj-
ect to enter the clinic involves the regulation of signaling
proteins. AP1903, ARIAD’s ‘bumped’ homodimerizing
drug based on the immunosuppressant FK506, has passed
a phase I trial. In the current phase II trial, AP1903 will be
used to induce the death of infused T cells if the cells
initiate an unwanted graft-versus-host response in leuke-
mia patients undergoing bone-marrow transplants. The
T cells are infected with a retrovirus ex vivo, selected for
the presence of the transfected gene based on a cell surface
marker, then injected into the recipient. AP1903 dimerizes
the cell death molecule Fas, based on an added FKBP
(FK506 binding protein) domain.
In a variation on the death program, your favorite stem
cell can be expanded using a dimerized growth receptor.
Although the program is just beginning, ‘‘it’s turned into
an embarrassment of riches,’’ says Clackson. Hepatocytes
may be the ¢rst test case.
ARIAD plans to activate transcription of therapeutic
genes using variants of the heterodimerizing immunosup-
pressant rapamycin, which binds both FKBP and FRAP
proteins. The system has been tested successfully in mon-
keys, as reported in Science in January 1999. The ¢rst
candidate protein for this approach will be Epo, because
it is an important therapeutic whose gene patent happens
to expire in 2004. Those genes that do not have expiring
patents will have to be licensed, on a gene-by-gene basis.
Berger plans to drive a hard bargain. ‘‘This is not going to
be given out for a few percent royalty,’’ he says. ‘‘You
don’t have a product without our technology. We have
the key, di¡erentiating technology.’’
In the research market, dimerizing reagents have already
been distributed to nearly 400 academic laboratories in
exchange for future intellectual property rights, and mar-
keting to biotech companies for use in research begins
January 2001.
The Tet alternative
In the research market, ARIAD faces sti¡ competi-
tion from the tetracycline-induced systems developed by
Hermann Bujard (University of Heidelberg, Germany).
According to Bujard ‘‘Tet is by far the most broadly
used and applied’’ transcriptional regulatory system,
although Clackson emphasizes that the ARIAD system
can also be used to regulate signal transduction proteins
directly.
Bujard deliberately chose tetracycline, he says, ‘‘because
with Tet you enter a whole ¢eld of known pharmacology
and chemistry.’’ The disadvantage, though, is that the tet-
racycline-responsive transcription regulators are bacterial,
not human proteins. ‘‘The real concern for gene therapy is
determining whether (the system) is by itself immunogen-
ic,’’ says Bujard. Based on mouse experiments, he says,
things look good.
Right now a more pressing concern is the lack of or-
ganizational impetus. Bujard is trying to buy back the
rights to his technology from BASF. ‘‘For such a huge
company this was not an important enough asset to fur-
ther develop,’’ he says. ‘‘They have decided they want to
sell it, and I think it should be put in a small company.’’
However those negotiations play out, Bujard is happy
with his system. ‘‘If you look at its impact in creating
especially conditional mutants in mice it has been just
fantastic,’’ he says. ‘‘Its main impact will be target valida-
tion. In gene therapy it may work; it may not work.’’
Yet another alternative was presented in the November
23 Nature by Ji-Won Yoon (Yonsei University, Seoul,
Korea), who cured diabetic mice with an insulin gene
hooked up to a glucose-responsive promoter. Regulated
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promoters don’t require pills, but they are not generaliz-
able like ARIAD’s system.
Expression on demand
When expression just can’t wait, ARIAD has the
RAPID system, in which a drug frees pre-made protein
from an aggregate, so it can be secreted promptly into the
bloodstream.
‘‘We had devised a (rapid delivery) scheme,’’ says Clack-
son, ‘‘but the key thing we needed was a conditional ag-
gregation domain (CAD). By pure chance we discovered
such a protein. It sat on the shelf for a while until we
realized that it would work with RAPID.’’
The CAD (now called FM) was one of the FKBPs en-
gineered with a hole to accommodate AP1903. FM was the
one variant that, unexpectedly, gave a positive two hybrid
when paired with itself. The aggregation was dissociated
by a monomeric version of AP1903.
Several FM domains strung together cause a protein to
aggregate in the endoplasmic reticulum unless the mono-
mer drug is added. Protein (e.g. insulin) release can be
detected by 15 min after drug addition, and peaks within
2 h. The system is particularly well suited to proteins that
must be pulsed rapidly to be e¡ective, such as parathyroid
hormone for osteoporosis or beta-endorphins for chronic
pain.
RAPID is far from the clinic, but has generated a Sci-
ence paper. So is science triumphing over business? Clack-
son thinks not. ‘‘We’ve got a more ruthless product focus
than we’ve had in the past,’’ he says.
And Berger has no regrets about the good science. ‘‘The
challenges have been scienti¢c,’’ he says. ‘‘These have been
hard programs to pursue. If you overcome these chal-
lenges you create something of great value, and I think
we are there now.’’
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